5 Orville Drive, Suite 200
77 articles with Sartorius
Sartorius, a leading international partner of life science research and the biopharmaceutical industry, is further growing its global production capacity with the expansion of its manufacturing site in Tunisia.
On the occasion of its virtual Annual General Shareholders' Meeting today, life science company Sartorius takes a positive look back at the past year and provides shareholders with details on further growth prospects.
The life science group Sartorius has presented its 2021 Annual Report.
The life science group Sartorius announced that, through its subgroup Sartorius Stedim Biotech, it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission.
Due to the excellent development of its core business, additional demand generated by the coronavirus pandemic, and several acquisitions, the life science group Sartorius closed fiscal 2021 with exceptionally strong growth and a jump in profitability.
Sartorius strengthens its bioanalytics portfolio by acquiring a majority stake in ALS Automated Lab Solutions
The life science group Sartorius is expanding its bioanalytics portfolio by acquiring a majority stake in ALS Automated Lab Solutions GmbH.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Biopharma and life sciences organizations from across the globe provide updates on their pipelines and businesses.
BioNet and Sartorius’ Company BIA Separations Collaborate on Production Process Development of mRNA Vaccines
BioNet, a leading biotech company manufacturing genetically engineered vaccines, and BIA Separations, now part of Sartorius, a leading biochromatography development and manufacturing company, announced the successful development of an optimized mRNA manufacturing process.
Sartorius grows dynamically and profitably - Substantial double-digit increases in sales and earnings
The life science group Sartorius has continued to grow dynamically and profitably. For the nine-month reporting period of 2021, the company listed on the DAX since September recorded significant double–digit growth rates in sales and earnings.
Matica Bio Announces Joint Research Agreement with Sartorius for the Development of Advanced Viral Vector Manufacturing Technology
Matica Biotechnology, Inc today announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry.
Marked by recent announcements of new manufacturing sites, headquarters and job creations, the life science industry continues to thrive despite the COVID-19 pandemic.
The life science company Sartorius, through its subgroup Sartorius Stedim Biotech, acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany.
Sartorius continues on its fast growth trajectory - significant double-digit increases in sales and earnings
The life science Group Sartorius has continued on its fast growth trajectory, closing the first half of 2021 with significant double-digit increases in both sales revenue and order intake.
Sartorius announces that it expects strong first–half performance and raises its forecast for the full year of 2021.
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.
The life science group Sartorius had an exceptionally strong start in fiscal 2021 and grew substantially in order intake1, sales revenue and earnings.
In just 30 months and despite facing a global pandemic, Penn State and collaborating companies have successfully established and advanced the industrial biotechnology ecosystem and talent pipeline at the university.
At virtual Annual General Shareholders' Meeting, shareholders granted discharge to the Executive Board and the Supervisory Board and approved the boards' proposals by a large majority.
The life science group Sartorius confirmed its preliminary figures for 2020 upon the release of its annual report.